Sedana Medical earnings for the third quarter of 2026 showed record sales for the period but a wider EBITDA loss, as the inhaled-sedation company continued preparing for potential US market entry. Results released on October 22 put net sales at SEK44.2 million, up 7% at constant exchange rates, while the group’s EBITDA loss widened to SEK7 million from SEK5.6 million a year earlier.
Key Takeaways
- Germany’s sales decline narrowed sharply, while other direct markets and distributors continued growing.
- Quarterly profitability weakened, although the business outside the US remained EBITDA-positive year to date.
- The FDA review has an April 16, 2027 target action date; US approval remains uncertain.
Table of Contents
- Sedana Medical earnings show a smaller decline in Germany
- Higher sales did not translate into stronger quarterly profitability
- Lower cash outflow supports preparations for the US review
- FDA timetable frames the potential US launch
- Conclusion
Sedana Medical earnings show a smaller decline in Germany
Germany, Sedana Medical’s largest market, recorded a 2% sales decline in local currency in the third quarter, compared with an 18% decline in the first half. Sales remained down 14% year to date, so the quarterly improvement did not yet amount to a return to growth.
Chief Executive Johannes Doll attributed the improvement to easing market headwinds and an internal sales acceleration program under new leadership. He said prioritized high-potential accounts were already growing faster than the national business.
Other direct markets grew 11% at constant exchange rates, slowing from 41% in the second quarter. Doll cited softer activity in Spain during the summer, including reduced intensive-care capacity. Distributor sales rose 27%, while contract manufacturing increased 47%, helped by a shipment delayed from June to July.
| Item | Details |
|---|---|
| Group EBITDA, year to date | Loss of SEK7 million, versus a SEK10 million loss a year earlier. |
| Operating cash flow, Q3 | Negative SEK3 million. |
| Investing cash flow, Q3 | Negative SEK9 million. |
| Staff excluding Malaysian subsidiary | 81 at quarter-end, compared with 83 a year earlier. |
Higher sales did not translate into stronger quarterly profitability
Gross profit rose to SEK30.8 million from SEK29.5 million, but the reported gross margin fell to 70% from 72%. Management said the margin was essentially stable at slightly above 70% after excluding the contract-manufacturing mix effect and a prior-year one-time reclassification.
Operating expenses increased to SEK45 million from SEK40 million. Management described underlying expenses as roughly flat after adjusting for foreign-exchange effects, higher depreciation and non-recurring items.
The business outside the US posted an EBITDA loss of SEK3.2 million for the quarter, versus a SEK1.7 million loss a year earlier. It nevertheless remained approximately SEK3 million EBITDA-positive year to date. Group year-to-date EBITDA also improved, separating the weaker quarterly result from the broader nine-month trend.
Lower cash outflow supports preparations for the US review
Total cash outflow narrowed to SEK14 million from SEK30 million in the second quarter and SEK17 million a year earlier. Sedana Medical ended the quarter with SEK40 million in cash and an undrawn SEK50 million credit facility.
Operating cash flow benefited from a SEK4.1 million working-capital contribution. That support matters when assessing the reduced cash burn: the improvement was not solely a reflection of operating profitability.
FDA timetable frames the potential US launch
The company’s FDA review timetable announcement sets April 16, 2027 as the target action date for its application covering isoflurane delivered through the Sedana Medical ACD Delivery System to sedate mechanically ventilated adult ICU patients. FDA acceptance of the filing was announced on August 19, 2026; acceptance for review is not approval.
Doll estimated the US market opportunity at at least $1 billion, roughly three times the potential of the company’s existing direct markets. This is management’s market-size estimate, not a sales forecast. Sedana Medical plans to launch through its own US commercial subsidiary if authorization is granted, while retaining the option of complementary partnerships.
An FDA-authorized Early Access Program is already operating at three hospitals. Management said three additional sites were preparing to start in the fourth quarter, providing a nearer-term operational milestone while the application remains under review.
Conclusion
Sedana Medical’s record third-quarter sales have yet to produce consistent quarterly EBITDA profitability. The next operational step is the planned expansion of US early-access sites, while April 16, 2027 remains the FDA’s target action date rather than a guaranteed approval or launch date.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
